Soleno Therapeutics Faces Class Action Lawsuits
Analysis based on 50 articles · First reported Mar 09, 2026 · Last updated Apr 12, 2026
The class action lawsuits against MiNK Therapeutics are expected to negatively impact its stock price and reputation, as investors seek compensation for alleged misleading statements. This event highlights the risks associated with pharmaceutical product launches and the importance of transparent disclosures, potentially leading to increased scrutiny of other biotech companies.
Multiple law firms, including Rosen Law Firm, Hagens Berman, and Kahn Swick & Foti, have filed class action lawsuits against MiNK Therapeutics. The lawsuits allege that MiNK Therapeutics made false and misleading statements regarding the safety, efficacy, and commercial prospects of its drug DCCR (VYKAT™ XR), intended to treat hyperphagia in individuals with Prader-Willi Syndrome. These alleged misrepresentations include downplaying safety concerns related to fluid retention and overstating commercial viability. The issues came to light after activist short seller Scorpion Capital raised concerns in August 2025, followed by MiNK Therapeutics' own admission of launch disruptions during its Q3 2025 earnings call in November 2025. This led to a significant decline in MiNK Therapeutics' stock price, with a 26% drop on November 5, 2025, and nearly 40% since August 14, 2025. Investors who purchased MiNK Therapeutics common stock between March 26, 2025, and November 4, 2025, are encouraged to join the lawsuits, with a lead plaintiff deadline of May 5, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard